New Risk • Jun 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m). New Risk • May 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m). 공시 • Mar 27
ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026 ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m). New Risk • Feb 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (NT$37m revenue, or US$1.2m). 공시 • Apr 14
ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant Patients ACRO Biomedical Co., Ltd. announced that its ABCcolla®? Collagen Ophthalmic Matrix has received regulatory approval from Taiwan'sMinistry of Health and Welfare (MOHW), with registration number: MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide. According to the World Health Organization (WHO), over 20 million people suffer from blindness due to corneal injuries or infections, yet only around 100,000 corneal transplants are performed annually, leading to a severe shortage. A report from Global Market Insights Inc. estimates the global corneal transplant market to reach $500 million in 2024, with an expected growth to $1 billion by 2033, at a compound annual growth rate (CAGR) of 7.59% from 2025 to 2033. ABCcolla®?Collagen Ophthalmic Matrix is the world's first and only product to utilize supercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhances biocompatibility, biodegradability, and tissue regeneration. The product has received patents in 15 countries and won the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Notably, there are currently no similar products available in the Taiwanese market. ACRO Biomedical has developed this product using porcine corneas, which closely resemble human corneal structure. Once all cellular components are removed, the material can serve as a biocompatible alternative to donated human corneas, reducing the risk of immune rejection. After rigorous clinical trials, ABCcolla®? Collogen Ophthalmic Matrix has been proven effective for patients suffering from corneal damage caused by melted, trauma, or infections, making it a viable corneal substitute in reconstruction surgeries. The company is preparing for product commercialization to meet market demand and improve patient quality of life. With an aging global population, increasing prevalence of corneal diseases, and rising awareness of vision health, the demand for corneal transplantation and related products is expected to grow steadily. By advancing this breakthrough technology, ACRO Biomedical aims to reduce dependency on donated corneas and restore sight for more patients worldwide. The company remains committed to ongoing innovation in regenerative medicine, striving to become a global leader in the field. Board Change • Apr 04
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Mar 28
ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025 ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan New Risk • Mar 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.17b market cap, or US$65.9m). New Risk • Dec 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$1.55b market cap, or US$47.5m). New Risk • Apr 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$1.61b market cap, or US$49.5m). 공시 • Apr 04
ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024 ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024. New Risk • Feb 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$2.37b market cap, or US$75.5m). New Risk • Aug 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.14b market cap, or US$67.7m). New Risk • Jul 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (NT$1.65b market cap, or US$53.1m). 공시 • Apr 10
ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022 ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022.